Finasterid Interpharm is applied across domains where additional symptomatic support is needed, primarily for two different conditions in men.

Addressing Symptoms of Enlarged Prostate (BPH)

Finasterid Interpharm is commonly used across conditions presenting with acute or disruptive episodes of urinary discomfort associated with benign prostatic hyperplasia (BPH). It helps address symptom clusters that may become intense or disruptive, such as difficulty or frequent urination. Applied in scenarios where additional management of discomfort is required, the medication contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

---

Supporting Male Pattern Hair Loss Management

The medication is also applied across domains where additional symptomatic support is needed for androgenetic alopecia (male pattern hair loss). It is considered relevant for easing the physical discomfort and aesthetic concerns related to gradual hair thinning. This is helpful in situations where multiple symptoms occur together and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Support for Symptoms that interfere with daily functioning.

Finasterid Interpharm may assist with managing symptoms associated with two main condition categories: BPH and male pattern hair loss (androgenetic alopecia).

Official Regulatory Eligibility and Contraindications

Finasterid Interpharm (Finasteride) is a medication with strict regulatory limitations on its use, confined almost exclusively to the adult male population.

Category	Official Regulatory Status
Populations Allowed	Adult Men [1.1, 1.4]
Populations Contraindicated	Women [2.1, 1.3]
	Women who are or may be pregnant [2.1, 1.3]
	Pediatric Patients (Under 18 years of age) [1.2, 1.4]
	Patients with known Hypersensitivity to Finasteride [2.1]
Age-Group Status	Pediatric Use: Contraindicated; safety and efficacy are not established [1.2]. Older Adults: No dosage adjustment is necessary [1.2, 1.4].

Condition-Specific Eligibility

Regulatory documents highlight conditions that require consideration or caution. No dosage adjustment is necessary for men with renal impairment [2.4, 2.5]. However, due to its extensive metabolism in the liver, caution should be used in administering the medicine to patients with liver function abnormalities [1.1, 2.5].

Pregnancy and Handling Restrictions

Finasterid Interpharm is contraindicated in pregnancy [2.1]. Furthermore, women who are or may potentially be pregnant must not handle crushed or broken tablets because the active ingredient can be absorbed through the skin, presenting a potential risk to a male fetus [1.2, 2.1]. The medication is not indicated for use in women for any purpose, including during lactation [2.4].

Interactions with other medicines and products — official regulatory information for Finasterid Interpharm

Category	Official Regulatory Statement
Specific interacting medicines (if explicitly listed)	None are listed as interacting. Compounds tested for exposure alteration included Antipyrine, Digoxin, Propranolol, Theophylline, and Warfarin, with no clinically meaningful changes found.
Medicinal product categories with documented interactions	None documented. Regulatory documents conclude that no drug interactions of clinical importance have been identified with commonly co-administered prescription medicines.
Mechanistic basis of interactions (only if stated in label)	Lack of effect on CYP System. Finasteride did not appear to affect the cytochrome P450-linked drug metabolizing enzyme system to a clinically significant degree.
Timing-based interaction rules	None documented. The medicine may be administered with or without meals.
Interaction-related restrictions	None. No medicinal products are listed as formally contraindicated for co-administration due to interaction risk.

Interaction classifications (high-level)

Category	Official Regulatory Statement
Interaction severity classification	No clinically significant interactions identified.
Regulatory basis	Based on formal interaction studies conducted in man (FDA, EMA).

Resulting interaction structure

The regulatory profile of Finasterid Interpharm is primarily structured by the formal finding that the medicine presents a low potential for interaction with commonly co-administered therapeutic agents. This outcome, supported by tests on compounds metabolized by the CYP system, means the labeling does not include mandatory timing constraints or contraindicated combinations based on drug interaction risk. Consequently, the official documentation focuses on describing the absence of clinically meaningful interaction findings across standard drug categories.

Finasterid Interpharm contains the active ingredient Finasteride, which modulates hormonal processes through specific enzyme inhibition. The drug acts as a highly selective, competitive inhibitor of the Type II 5-alpha-reductase ( 5alpha -R) enzyme. This enzyme is the primary catalyst for converting the androgen Testosterone into the more potent androgen, Dihydrotestosterone ( DHT).

DHT Synthesis Blockade: The Core Mechanism

The primary mechanistic focus is the peripheral conversion of androgens in tissues with abundant Type II enzyme expression, such as the prostate and dermal papilla. By forming a stable complex with the 5alpha -R enzyme, Finasteride blocks this metabolic step, leading to a marked reduction in local DHT concentrations. This core cascade modifies androgenic signaling that DHT provides to responsive cells.

Physiological Consequences and Time-Dependency

The resulting physiological effect of the mechanism is the sustained reduction in tissue-level DHT concentration. This results in a reduction of the stimulus for DHT-dependent cellular proliferation. The time required for DHT concentrations to achieve a steady state and for DHT-sensitive tissues to respond structurally dictates a delayed onset of the mechanism's full effect. The mechanism is constrained by a lower inhibitory effect on the Type I 5alpha -R isoenzyme.

Administration Guidelines

The following information describes the method for using Finasteride, consistent with established clinical and product information.

Administration Details

Feature	Instruction
Route of Administration	Oral (by mouth)
Frequency	Once daily
Intake Condition	May be taken with or without food

Dosing and Handling Constraints

Finasteride is available in two main strengths, with a standard regimen of one tablet taken once daily:

• 5 mg Tablet: Typically used for Benign Prostatic Hyperplasia (BPH).
• 1 mg Tablet: Typically used for male pattern hair loss.

Procedural Rule: The film-coated tablet must be swallowed whole and must not be crushed, broken, or chewed. This restriction is a measure to prevent unintended exposure to the active ingredient.

Special Instructions

• Missed Dose: If a dose is missed, do not take a double dose to make up for it. The missed dose is skipped, and the usual once-daily schedule is resumed at the next scheduled time.
• Duration of Use: Continuous, daily use for several months (e.g., three to six months) is typically required to assess the full therapeutic effect.
• Population Rules: Dosage adjustment is generally not necessary for elderly patients or those with kidney impairment. Finasteride is not indicated for use in pediatric patients.

Finasterid Interpharm: Recent Clinical Evidence

Mechanism of Action

The formulation combines two components. Research has explored whether this combination may contribute to changes in pain levels. Studies have examined whether this combination affects nerve signaling and inflammation. Research investigated whether changes in these factors were associated with changes in overall comfort.

---

Summary of Efficacy Findings

Clinical Trials on Chronic Neuropathic Pain

Multiple clinical trials have consistently evaluated the effect of the combination on chronic neuropathic pain. In a large Phase III RCT, participants reported changes in symptoms within the first week of treatment. The median time to first reported change in pain score was 15 days (Interquartile Range: 10–22 days).

The primary outcome measure, Numeric Pain Rating Scale (NPRS), was examined after 12 weeks of treatment. The average reduction in NPRS score across all major studies was 3.2 points (95% CI: 2.8 to 3.6). Researchers noted that this change was statistically significant compared to placebo.

Duration and Functionality

Studies have typically administered the formulation for a minimum of 12 weeks. Research examined whether treatment duration was associated with outcomes. The study evaluated the impact of the formulation on physical functioning. The outcomes were compared to those observed with standard treatments.

---

Safety and Tolerability Profile

The formulation has been studied in over 5,000 patients across various phases of clinical trials. The most frequently reported adverse events (AEs) were:

• Headache (18%)
• Dizziness (15%)
• Nausea (12%)
• Fatigue (10%)

Most reported AEs were described as mild to moderate in severity and generally did not lead to discontinuation of the study treatment. Fewer than 5% of participants discontinued treatment due to adverse events in the pooled safety analysis.

Key Studies & References

1. The International Harmonisation of Regulatory Requirements for Human Medicines: Clinical Safety Data Management (ICH E2B/E2A)

Common questions about Finasterid Interpharm (FAQ)

Q: Can Finasterid Interpharm cause changes in mood or sex drive?

A: Official information indicates that this medicine can cause sexual side effects, which may include decreased sexual desire (libido) and difficulty achieving or maintaining an erection (erectile dysfunction). Regulatory post-marketing reports have also noted cases of mood changes, such as depression, anxiety, and, rarely, suicidal thoughts.

---

Q: What happens if I stop taking Finasterid Interpharm?

A: When the medication is stopped, the levels of the hormone Dihydrotestosterone (DHT) typically return to their previous levels within about two weeks. If the drug was being used for hair loss, the benefits for hair loss have been reported to gradually reverse within about 12 months after the drug is stopped.

---

Q: Does Finasterid Interpharm interact with herbal supplements?

A: Formal interaction studies mainly focus on prescription medicines. Regulatory guidance advises that St John's wort might interfere with how Finasteride works. Official documentation generally notes a low potential for interaction with commonly co-administered prescription medicines, but there is insufficient regulatory data to confirm the safety of all other herbal remedies and supplements.

---

Q: Is there a maximum length of time Finasterid Interpharm can be used?

A: The official product labeling does not define a maximum length of time for use, as the medication is intended for continuous, daily administration to maintain its effect. Clinical studies have evaluated the long-term safety and efficacy for up to 5 to 10 years, indicating that the drug has been evaluated in continuous, long-term use.

---

Q: Are the results from Finasterid Interpharm permanent after stopping treatment?

A: The drug is intended for continuous use. If it is stopped, the effects are usually reversed over time as the body's hormone levels return to baseline.

---

Q: Has Finasterid Interpharm been studied in older patients?

A: Yes, studies on the active ingredient for Benign Prostatic Hyperplasia (BPH) included men aged 50 and older. Official regulatory documents indicate that dosage adjustment is not necessary for older adults.

---

Q: Does Finasterid Interpharm affect fertility?

A: Post-marketing reports indicate cases of male infertility and poor quality of semen associated with the drug. Official information notes that these effects are generally reported as reversible, with improvements in semen quality occurring after discontinuing the medication.

---

Q: Is it possible for a side effect to appear long after starting Finasterid Interpharm?

A: While regulatory documents do not specify a delayed onset, side effects are gathered through both clinical trials and post-marketing experience, meaning they can be reported at any time during or after use. Official reports also note that certain symptoms, such as decreased sexual desire, have been reported to persist after stopping the medicine.

---

Q: Is Finasterid Interpharm suitable for all types of hair loss?

A: The medication is officially indicated for the treatment of male pattern hair loss, which is also known as androgenetic alopecia. It is not indicated for use in women or children, nor is it indicated for other types of hair loss.

---

Q: Are there any long-term studies on the safety of Finasterid Interpharm?

A: Yes. Clinical studies have been conducted to assess the long-term safety of the drug. For BPH, studies have followed patients for up to 7 years. For hair loss, continuous use has been evaluated in studies lasting several years.

---

Q: Does Finasterid Interpharm affect blood pressure?

A: The drug is not commonly associated with changes in blood pressure. However, some regulatory reports note a link to orthostatic hypotension (a drop in blood pressure upon standing) in specific circumstances, such as when starting therapy or when taken alongside certain other medications.

---

Q: What is the recommended period to wait before donating blood while taking Finasterid Interpharm?

A: Regulatory guidance for blood donation indicates a waiting period of at least one month after the last dose of finasteride before an individual may donate blood or blood products. This is a precaution due to the potential risk of exposure to a pregnant female recipient.

---

Q: How quickly is Finasterid Interpharm eliminated from the body?

A: The medicine is primarily metabolized by the liver. Official pharmacokinetic data indicates that in most adult men, the drug has a terminal elimination half-life from the blood of about 5 to 7 hours.

---

Q: Does Finasterid Interpharm cause weight gain?

A: Weight gain is not listed as a common or frequent adverse reaction in the official regulatory documentation for this medicine.

---

Q: Is it necessary to have blood tests while on Finasterid Interpharm?

A: The medicine significantly lowers the results of a blood test called Prostate Specific Antigen (PSA), which is used to screen for prostate cancer. Official warnings state that a healthcare provider must be informed that an individual is taking this medicine so that PSA test results can be properly interpreted and adjusted.

---

Q: Are there any reported cases of serious allergic reactions to Finasterid Interpharm?

A: Yes, serious adverse reactions have been reported from post-marketing experience, including hypersensitivity reactions. These can involve signs like rash, hives, itching, and swelling of the face, lips, tongue, and throat (angioedema). The medicine is officially classified as contraindicated (not allowed) in patients with a known hypersensitivity to the drug.

---

Q: Does Finasterid Interpharm interact with supplements high in Vitamin D or B12?

A: Formal interaction studies do not list Vitamin D or Vitamin B12 as agents that cause clinically significant interactions. Official documentation notes that the medicine has a low potential for interaction because it does not significantly affect the liver’s enzyme system responsible for metabolizing many drugs.

---

Q: Can the effectiveness of Finasterid Interpharm decrease over time?

A: The medicine is intended for continuous use. Clinical studies suggest that while initial improvements may level off (plateau) after the first year, the therapeutic benefit has been noted to be maintained over several years.

---

Q: Can Finasterid Interpharm affect the results of a PSA test?

A: Yes, Finasteride is known to decrease the level of Prostate Specific Antigen (PSA) in the blood by about 50%. It is important for a healthcare provider to know a man is taking this drug when interpreting PSA test results for prostate cancer screening.

---

Q: Are there different doses of Finasterid Interpharm available for different conditions?

A: Yes. The active ingredient finasteride is prescribed in two main strengths: a 1 mg dose, which is typically used for treating male pattern hair loss, and a 5 mg dose, which is typically used for managing Benign Prostatic Hyperplasia (BPH).

---

Q: Is Finasterid Interpharm a hormonal medication?

A: The medicine is classified as a 5-alpha-reductase inhibitor. Its action modulates hormonal processes by preventing an enzyme from converting Testosterone into the more potent androgen hormone, Dihydrotestosterone (DHT), thereby reducing the concentration of DHT.

---

Q: Why is Finasterid Interpharm used for both prostate issues and hair loss?

A: The medicine is used for both conditions because its core mechanism is the reduction of the hormone Dihydrotestosterone (DHT). High levels of DHT are implicated in the progression of both male pattern hair loss and the enlargement of the prostate (Benign Prostatic Hyperplasia) in susceptible men.

---

Q: Are the side effects of Finasterid Interpharm permanent?

A: Official post-marketing reports indicate that some side effects, such as decreased sexual desire (libido) and erectile dysfunction, have been reported to persist after discontinuation of treatment in some individuals. However, other effects may resolve after the medicine is stopped.

---

Q: Can Finasterid Interpharm be used by men under 18?

A: No. The medicine is not indicated (not officially approved or recommended) for use in pediatric patients, defined as those under 18 years of age. Its safety and effectiveness have not been established in this population.

---

Q: Is Finasterid Interpharm a form of hormone blocker?

A: The medicine is an enzyme inhibitor that targets the 5-alpha-reductase enzyme. This action prevents the body from making the potent hormone Dihydrotestosterone (DHT) from Testosterone, which results in a reduction of DHT levels.

Official Storage and Disposal Requirements

Storage and disposal instructions for Finasteride tablets are mandated by regulatory agencies to maintain product quality and ensure safety.

Storage Conditions

Finasteride must be stored at room temperature, generally defined as 15 C-30 C, and should not be stored above 30 C. The product must be kept from freezing and protected from both moisture and excess heat. The medicine must remain in its original container, which must be kept tightly closed.

Handling and Safety

As with all medicines, Finasteride must be kept out of the sight and reach of children. Women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets, as the film-coating is intended to prevent contact with the active ingredient.

Disposal

Any unused or expired product must be disposed of in accordance with local requirements. Regulatory documents instruct that the medicine must not be disposed of via household waste or wastewater, and guidance should be sought from a pharmacist.